Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 8 records per page: next > | last >>
pages: 1 2 3 4 5 6 7 8 presentations: 1 to 25 of 196
What Can Proteomics Teach Us That Genetics Cannot?
State of the art in proteomics technologies
Daniel C. Liebler
Vanderbilt University, Nashville, TN, United States
from AACR Annual Meeting 2015 on April 18, 2015 8:00 AM-10:00 AM
What Can Proteomics Teach Us That Genetics Cannot?
Leveraging the synergy between genomics and proteomics through bioinformatics
Bing Zhang
Vanderbilt University School of Medicine, Nashville, TN, United States
from AACR Annual Meeting 2015 on April 18, 2015 8:00 AM-10:00 AM
What Can Proteomics Teach Us That Genetics Cannot?
Proteogenomic analysis of colon tumors and cell lines
Robbert J.C. Slebos
Vanderbilt University, Nashville, TN, United States
from AACR Annual Meeting 2015 on April 18, 2015 8:00 AM-10:00 AM
What Can Proteomics Teach Us That Genetics Cannot?
Dissecting signaling pathways in cancer using proteomics
Akhilesh Pandey
Johns Hopkins Univ., Baltimore, MD, United States
from AACR Annual Meeting 2015 on April 18, 2015 8:00 AM-10:00 AM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 3: New Opportunities in Epigenetic Therapies
Introduction
Guowei Fang
AbbVie, Inc., North Chicago, IL, United States
from AACR Annual Meeting 2015 on April 18, 2015 1:00 PM-3:00 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 3: New Opportunities in Epigenetic Therapies
Chemical probes for epigenetic proteins
Paul Brennan
University of Oxford, Oxford, United Kingdom
from AACR Annual Meeting 2015 on April 18, 2015 1:00 PM-3:00 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 3: New Opportunities in Epigenetic Therapies
Discovering chemical probes of histone methyltransferases
H. Ümit Kaniskan
Icahn School of Medicine at Mt. Sinai, New York, NY, United States
from AACR Annual Meeting 2015 on April 18, 2015 1:00 PM-3:00 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 3: New Opportunities in Epigenetic Therapies
Discovery of EPZ015666: A first-In-class PRMT5 inhibitor with potent in vitroand in vivo activity
Kenneth W. Duncan
Epizyme, Inc., Cambridge, MA, United States
from AACR Annual Meeting 2015 on April 18, 2015 1:00 PM-3:00 PM
Cancer Drug Discovery 2015: Challenges and Opportunities for Academia and Industry
Introduction
Donald Ogilvie
Cancer Research UK Manchester Institute, Manchester, United Kingdom
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Cancer Drug Discovery 2015: Challenges and Opportunities for Academia and Industry
Chemical biology approaches to target validation in cancer
Julian Blagg
Inst. of Cancer Research, Sutton, Surrey, United Kingdom
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Cancer Drug Discovery 2015: Challenges and Opportunities for Academia and Industry
Collaborating with industry to find chemical hits versus difficult targets
Allan M. Jordan
Cancer Research UK Manchester Inst., Manchester, United Kingdom
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Cancer Drug Discovery 2015: Challenges and Opportunities for Academia and Industry
Reducing the PAIN in academic drug discovery
Jonathan B Baell
Monash University, Parkville, Australia
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Cancer Drug Discovery 2015: Challenges and Opportunities for Academia and Industry
Partnering with academia in early drug discovery: An industry perspective
Dashyant Dhanak
Janssen Research Development, LLC, Spring House, PA, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism
Optimization of glutaminase inhibitors for the treatment of cancer
Rene M. Lemieux
Agios Pharmaceuticals, Cambridge, MA, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism
Discovery of in vivo inhibitors of Lactate Dehydrogenase A (LDHA)
Hans Purkey
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism
Discovery of a Potent, Selective, NAMPT inhibitor from the Pyridyloxyacetyl-Dihydro-Isoquinoline-Sulfonamide series that demonstrated robust efficacy and improved tolerability with nicotinic acid co-administration
Timothy P. Burkholder
Eli Lilly and Company, Indianapolis, IN, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism
MCT1: The journey from phenotypic screen hit to clinical candidate
Jon Winter
AstraZeneca R&D, Cheshire, United Kingdom
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Systems Approaches to Cancer Metabolism
Untargeted metabolomics: Technologies to study cancer metabolism at the global scale
Gary Patti
Washington University in St. Louis, St. Louis, MO, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Systems Approaches to Cancer Metabolism
Understanding metabolic heterogeneity in cancer cells and human tumors
Ralph J. DeBerardinis
UT Southwestern Medical Center, Dallas, TX, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Systems Approaches to Cancer Metabolism
Similarity and diversity in cancer cell metabolism
Dennis Vitkup
Columbia University, New York, NY, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Systems Approaches to Cancer Metabolism
Integrating metabolomics with transcriptional profiling: Statistical aspects of hypothesis generating systems data analysis
Edward Driggers
General Metabolics, Winchester, MA, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
Imaging of Immunotherapy in Action
Non-immunogenic PET reporter imaging of HSC transplants and T cell immunotherapies
Owen N. Witte
UCLA, Los Angeles, CA, United States
from AACR Annual Meeting 2015 on April 19, 2015 1:00 PM-3:00 PM
Imaging of Immunotherapy in Action
Fluorine-19 MRI cell tracking for immune cell detection and quantification in vivo
Eric T. Ahrens
USCD, La Jolla, CA, United States
from AACR Annual Meeting 2015 on April 19, 2015 1:00 PM-3:00 PM
Imaging of Immunotherapy in Action
Visualising immune responses in cancer patients
Jolanda de Vries
Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands
from AACR Annual Meeting 2015 on April 19, 2015 1:00 PM-3:00 PM
New Drugs on the Horizon 1
PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma
Eli M. Wallace
Peloton Therapeutics, Inc., Dallas, TX, United States
from AACR Annual Meeting 2015 on April 19, 2015 1:00 PM-3:00 PM
<< first | < prev page: of 8 records per page: next > | last >>
pages: 1 2 3 4 5 6 7 8 presentations: 1 to 25 of 196